Amivantamab-Lazertinib: A Combination Lung Cancer Therapy

Amivantamab combined with lazertinib is a two-drug regimen for advanced non-small cell lung cancer (NSCLC) driven by specific mutations in the epidermal growth factor receptor (EGFR) gene. In the landmark MARIPOSA trial, the combination extended the median time patients lived without their cancer worsening to about 24 months, compared with roughly 17 months for osimertinib alone, which had been the standard first-line treatment for years. The regimen attacks tumors through multiple pathways at once, and that redundancy is the core of its appeal, though it comes with a heavier side-effect burden and significant cost considerations that complicate the picture.

What Each Drug Does

Amivantamab is a bispecific antibody, meaning it latches onto two different targets on the surface of cancer cells: EGFR and MET. Most EGFR-targeted therapies work inside the cell, blocking the enzyme that transmits growth signals. Amivantamab works from the outside. It binds to EGFR’s extracellular domain and separately binds MET, a receptor that cancer cells often hijack as an escape route when EGFR alone is blocked. On the MET side, amivantamab blocks a growth factor called HGF from docking with the receptor, shutting down that signaling channel.¹ Beyond receptor blocking, the antibody recruits immune cells. Its modified structure enhances the ability of monocytes and macrophages to strip receptors off cancer cells through a process called trogocytosis, essentially chewing away at the tumor’s signaling machinery.²

Lazertinib is a daily oral pill and a third-generation EGFR tyrosine kinase inhibitor (TKI). It works inside the cell, forming a permanent bond to a specific spot in the EGFR enzyme’s active site. It was designed to be highly selective for the most common EGFR mutations that drive lung cancer, including a resistance mutation called T790M that can emerge during earlier treatments.³ Structural studies show lazertinib binds EGFR through a distinctive chemical arrangement that gives it effective activity against the common L858R and T790M double-mutant form of EGFR.⁴

Why Combining Them Makes Sense

EGFR-mutant lung cancers are remarkably good at finding workarounds when you attack them from one direction. Block the EGFR enzyme with a TKI, and tumors can upregulate MET signaling or develop new EGFR mutations. Amivantamab addresses this by simultaneously covering the MET escape route and by working outside the cell where intracellular resistance mutations are irrelevant. Lazertinib handles the direct EGFR enzyme blockade inside the cell. Together, the two drugs create overlapping pressure that is harder for tumors to evade. This is the rationale that drove the MARIPOSA clinical trial program.

First-Line Results From MARIPOSA

The MARIPOSA trial compared amivantamab plus lazertinib head-to-head against osimertinib as the first treatment for patients with EGFR-mutant advanced NSCLC. The combination extended median progression-free survival (PFS) to 23.7 months compared with 16.6 months for osimertinib, a statistically significant difference. Response rates were similar in both arms, with about 86% of patients in the combination group and 85% in the osimertinib group showing tumor shrinkage. But among those who responded, the combination kept working longer: the median duration of response was about 26 months versus roughly 17 months for osimertinib.⁵

Whether longer PFS translates into longer overall survival is the question patients care about most, and data is still maturing. At an early interim analysis, there was a trend favoring the combination, with a hazard ratio for death of 0.80, but the result had not yet reached statistical significance.⁵ A subset analysis of Asian participants with longer follow-up (nearly 39 months) was more encouraging: median overall survival was not yet reached for the combination versus about 38 months for osimertinib, with 61% of combination patients alive at three years compared with 53% on osimertinib.⁶ These numbers are promising, but subset analyses are not definitive on their own, and the full population’s overall survival data will take more time to mature.

Who Benefits Most and Blood-Based Clues

Not every patient with EGFR-mutant lung cancer gets the same degree of benefit from the combination. A secondary analysis from MARIPOSA looked at circulating tumor DNA (ctDNA), fragments of tumor DNA detectable in a blood sample, as a way to identify patients with higher-risk disease. Among patients who had detectable ctDNA at baseline, the combination extended median PFS to about 20 months compared with roughly 15 months for osimertinib. The advantage was even more striking in patients whose ctDNA did not clear after a few cycles of treatment: the combination’s median PFS was about 17 months versus 9 months for osimertinib in that harder-to-treat group.⁷ This suggests the combination may be especially valuable for patients whose disease signals higher aggressiveness through persistent tumor DNA in the blood.

An indirect comparison of phase 3 trials also raised the question of whether patients with certain characteristics might do better on the alternative combination of osimertinib plus chemotherapy. That analysis suggested osimertinib-chemotherapy could have an edge in patients with brain metastases, without liver metastases, or with the L858R mutation subtype, though the comparison was indirect and the authors were careful to call it hypothesis-generating rather than definitive.⁸ The L858R finding is worth watching: a small real-world study of amivantamab as a later-line salvage therapy found far better responses in patients with L858R mutations compared with exon 19 deletions.⁹ Though that was a tiny study in the salvage setting, it raises interesting questions about whether mutation subtype should factor into first-line treatment decisions.

Side Effects and How to Manage Them

The combination’s side-effect profile is heavier than osimertinib alone. The most important adverse events fall into a few categories:

Skin reactions: Rash and paronychia (painful, inflamed nail beds) are the most common skin-related side effects, consistent with EGFR blockade. A study called COCOON evaluated whether giving patients prophylactic oral and topical antibiotics plus moisturizer from the start could reduce these problems, and it cut the rate of moderate-to-severe skin reactions roughly in half compared with standard management.¹⁰
Blood clots: Venous thromboembolism (VTE) is a significant concern. In the MARIPOSA trial, VTE events were reported in 37% of patients on the combination versus 9% on osimertinib, though serious grade 4 or 5 events were uncommon in both groups.¹¹ Prophylactic blood thinners are now recommended for the first four months of combination treatment.¹²
Infusion reactions: Because amivantamab is given through an IV, reactions during infusion (fever, chills, shortness of breath) are common, particularly during the first dose.
Other effects: Swelling (edema), low albumin levels, and mouth sores are also associated with the regimen.¹³

Asia-Pacific consensus guidelines now recommend a proactive approach: prophylactic anticoagulants for VTE prevention, prophylactic minocycline or doxycycline for skin reactions, and regular moisturizing as part of the treatment plan from day one.¹³ The theme across the literature is that many of these side effects are predictable and can be significantly mitigated with upfront prevention, but they require a care team that is prepared and attentive.

Subcutaneous Injection as an Alternative to IV

Intravenous amivantamab infusions are time-consuming, especially in the early cycles, and the high rate of infusion-related reactions has been a practical barrier. The PALOMA-3 trial tested whether a subcutaneous (under-the-skin) injection could deliver equivalent drug exposure with fewer hassles. It could. The subcutaneous version met its primary goals of matching the IV version’s drug levels in the blood, and response rates were comparable at about 30%.¹⁴

The practical advantages were clear. Only 13% of patients in the subcutaneous group experienced infusion-related reactions compared with 66% in the IV group. VTE rates also dropped, from 14% with IV to 9% with subcutaneous.¹⁵ For patients and clinics, subcutaneous administration means shorter visits, fewer reactions to manage, and potentially lower clot risk. It is likely to become the preferred route as it gains broader regulatory clearance.

After Osimertinib Fails

One of the most challenging moments in treating EGFR-mutant lung cancer comes when the first-line therapy stops working. For the many patients currently receiving osimertinib as their initial treatment, the MARIPOSA-2 trial tested whether adding amivantamab (with or without lazertinib) to standard chemotherapy could improve outcomes after osimertinib failure. Both amivantamab-containing regimens significantly outperformed chemotherapy alone. Amivantamab plus chemotherapy extended median PFS from about 4 months to roughly 6 months, and the triple combination of amivantamab, lazertinib, and chemotherapy pushed it to about 8 months. Response rates roughly doubled, from 36% with chemotherapy alone to about 64% with the amivantamab-containing regimens.¹⁶

A particularly useful finding from MARIPOSA-2 is that amivantamab plus chemotherapy improved PFS regardless of why osimertinib stopped working. Whether the resistance was due to MET amplification, secondary EGFR mutations, EGFR/MET-independent pathways, or an unknown mechanism, the benefit remained consistent.¹⁷ This is meaningful because clinicians often cannot identify the resistance mechanism quickly, and knowing the treatment works broadly gives confidence to start it without waiting for extensive molecular testing.

Brain and Leptomeningeal Metastases

Brain metastases are common in EGFR-mutant lung cancer and historically difficult to treat. Amivantamab is a large antibody molecule, and there was reasonable skepticism about whether it could reach tumors behind the blood-brain barrier in meaningful concentrations. A phase 2 study tested the combination in patients with brain metastases or leptomeningeal disease (cancer in the membranes surrounding the brain) who had already received prior treatment. Half of the patients with brain metastases showed a response, while a third of those with leptomeningeal disease responded.¹⁸ These response rates are notable for a setting that has very limited treatment options, though the median PFS was modest at about 6 to 8 months. The activity likely reflects lazertinib’s ability to cross into the brain (it was designed to do so) combined with whatever partial access amivantamab achieves through areas where the blood-brain barrier is disrupted by the tumor itself.

Exon 20 Insertion Mutations

Most EGFR-mutant lung cancers carry either exon 19 deletions or L858R point mutations, the “classic” mutations that respond well to TKIs. But about 10% of EGFR mutations are exon 20 insertions, which are inherently resistant to standard TKIs because the mutations alter the shape of the drug-binding pocket in a way that prevents the pill from fitting properly. Amivantamab sidesteps this problem entirely: it binds the outside of the EGFR protein rather than the enzyme’s internal pocket, so the shape of that pocket is irrelevant.¹⁹ This was one of amivantamab’s earliest clinical applications and an area of genuine unmet need.²⁰

More recently, the combination of amivantamab plus lazertinib has been tested in patients with atypical EGFR mutations (a broader category that includes exon 20 insertions along with other uncommon variants). In the CHRYSALIS-2 study, the overall response rate was about 52%, with a median PFS of roughly 11 months. Among patients who were treatment-naïve, the numbers were even better: a 57% response rate and a median PFS nearing 20 months.²¹ For a patient population that has historically had few options, these results represent a meaningful step forward.

The Cost Problem

The combination’s clinical benefits come with an economic asterisk that is hard to ignore. Cost-effectiveness analyses have consistently found that amivantamab plus lazertinib is extraordinarily expensive relative to the survival gains it delivers. One analysis comparing the combination to osimertinib alone found an incremental cost of over $1.3 million for an additional 1.11 quality-adjusted life years (QALYs), producing a cost per QALY well above $1.2 million, far exceeding conventional thresholds for cost-effectiveness in any country.²²

A separate analysis that also included osimertinib plus chemotherapy as a comparator found that amivantamab-lazertinib’s cost per QALY exceeded $300,000 relative to osimertinib alone, and was more than $400,000 per QALY compared with osimertinib-chemotherapy. In U.S. pricing, the numbers were even steeper, exceeding $1.5 million and $2.6 million per QALY, respectively.²³ In both analyses, drug acquisition costs were the primary driver. Unless pricing changes substantially, the combination’s value proposition will remain a point of contention between its clinical promise and healthcare budget realities. The subcutaneous formulation may reduce some administration costs but does not meaningfully address the drug pricing itself.

What Practical Choices Patients and Oncologists Face

For a patient newly diagnosed with EGFR-mutant advanced NSCLC carrying a classic mutation, the treatment landscape now has several first-line contenders: osimertinib alone, osimertinib plus chemotherapy, and amivantamab plus lazertinib. The combination offers the longest PFS in a head-to-head trial, but it carries more side effects, requires more monitoring and prophylactic medications, and costs dramatically more. Overall survival data are still maturing. Osimertinib alone remains a simpler, well-tolerated option with a long track record. Osimertinib plus chemotherapy offers its own PFS gains with a different toxicity profile.

In practice, the choice depends on the individual. A patient with high-risk features like persistent ctDNA or liver metastases may stand to benefit more from the combination’s multi-pronged approach. A patient who values treatment simplicity, who has limited access to infusion centers, or who has a history of blood clots might lean toward osimertinib-based regimens. Insurance coverage and out-of-pocket costs will play a role in many healthcare systems. And as overall survival data continues to mature, the picture will sharpen. For patients with atypical EGFR mutations or those who have already progressed on osimertinib, the calculus tilts more clearly toward amivantamab-based regimens, simply because fewer alternatives exist with comparable evidence.